GlaxoSmithKline
GSK
A$58.37
Share price
0.03%
Change (1 day)
1.67%
Change (1 year)
Categories
Market capitalization of GlaxoSmithKline (GSK)
Market cap: A$118.67 Billion
As of July 2025 GlaxoSmithKline has a market cap of A$118.67 Billion. This makes GlaxoSmithKline the world's 271th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of GlaxoSmithKline from 1996 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | A$118.67 B | 6.16% |
| 2024 | A$111.78 B | -0.12% |
| 2023 | A$111.92 B | 5.88% |
| 2022 | A$105.70 B | -29.76% |
| 2021 | A$150.49 B | 26.11% |
| 2020 | A$119.34 B | -28.21% |
| 2019 | A$166.23 B | 24.66% |
| 2018 | A$133.34 B | 18.14% |
| 2017 | A$112.87 B | -13.65% |
| 2016 | A$130.71 B | -3.87% |
| 2015 | A$135.97 B | 6.83% |
| 2014 | A$127.28 B | -12% |
| 2013 | A$144.63 B | 42.11% |
| 2012 | A$101.77 B | -9.41% |
| 2011 | A$112.34 B | 11.99% |
| 2010 | A$100.31 B | -17.82% |
| 2009 | A$122.07 B | -10.9% |
| 2008 | A$137.00 B | -13.69% |
| 2007 | A$158.74 B | -17.59% |
| 2006 | A$192.61 B | -4.36% |
| 2005 | A$201.40 B | 10.78% |
| 2004 | A$181.80 B | 2.62% |
| 2003 | A$177.16 B | -11.54% |
| 2002 | A$200.27 B | -33.53% |
| 2001 | A$301.30 B | -4.37% |
| 2000 | A$315.07 B | 103.55% |
| 1999 | A$154.78 B | -24.78% |
| 1998 | A$205.77 B | 56.66% |
| 1997 | A$131.34 B | 85.38% |
| 1996 | A$70.85 B |
End of Day market cap according to different sources
On Jul 7th, 2025 the market cap of GlaxoSmithKline was reported to be:
A$119.57 Billion
A$118.03 Billion
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 AstraZeneca AZN | A$329.98 B | 178.05% | 🇬🇧 UK |
 Pfizer PFE | A$220.52 B | 85.82% | 🇺🇸 USA |
 Merck MRK | A$310.58 B | 161.70% | 🇺🇸 USA |
 Novartis NVS | A$370.86 B | 212.50% | 🇨🇭 Switzerland |
 Sanofi SNY | A$182.43 B | 53.72% | 🇫🇷 France |
 Teva Pharmaceutical Industries TEVA | A$29.53 B | -75.11% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | A$1.89 B | -98.41% | 🇺🇸 USA |